European Commission approves Pfizer's PREVENAR 20® to help protect infants and children against pneumococcal disease
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Novartis presents new data on safety and efficacy of Zolgensma
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
Pfizer announces positive top-line data for full season two efficacy of ABRYSVO® for RSV in older adults
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
European Commission approves Pfizer's VELSIPITY® for patients with moderately to severely Active ulcerative colitis
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Acquisition of Icosavax completed
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
More Pharma News ...
- Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
- The American Cancer Society and Pfizer announce a $15 million, three-year initiative to bridge the gap in cancer care disparities
- Bayer aims to sustainably improve performance with new organization
- Pfizer recommends shareholders reject the below-market mini-tender offer by TRC Capital Investment Corporation
- European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
- Bayer's AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)
- TIVDAK® supplemental Biologics License Application accepted for Priority Review by FDA for patients with recurrent or metastatic cervical cancer